Navigation Links
Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
Date:6/12/2013

acks.local/funds/etf/FBT/profile?q=BBH">BBH-Free Report)

This ETF tracks the Market Vectors US Listed Biotech 25 Index, a benchmark of 25 companies in the biotech sector. The fund charges a reasonable 35 basis point fee per year, and sees decent volume on assets of about $300 million (see Two Sector ETFs to Buy in 2013).

The ETF is heavily focused on large caps and growth stocks, as more than two-thirds of the portfolio falls in the large cap category, while about 80% is classified as growth. With this focus, it shouldn't be too surprising to note that the ETF doesn't really pay anything in yield, and that it isn't an income choice for investors.

In terms of holdings, large biotech firms take the top three spots and account for about 36% of assets, suggesting a relatively heavy level of concentration. Six other companies make up over 4% though, so there is a decent amount of diversification.

From a performance perspective, the ETF has been extremely solid, adding about 30% over the past six months. The fund is also up 55% from a one year look, thoroughly crushing similar funds and the broad market in the time frame.

iShares Nasdaq Biotechnology ETF (Nasdaq: IBB-Free Report)

This fund follows the NASDAQ Biotechnology Index, a benchmark of about 120 companies involved in biomedical research. The ETF charges 48 basis points a year in fees, and sees great volume on assets of just over $3 billion.

Growth stocks are once again a big part of this fund accounting for about 80% of the total. Ho
'/>"/>

SOURCE Zacks Investment Research, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. As Released on 30 December, 2011: Novogen Modifies ADR Program and Makes Further Investment Into Marshall Edwards
2. Life Technologies to Present at Upcoming Investment Conferences in February
3. New investment aims to establish the UK as a global graphene research hub
4. Amarantus BioSciences to Present at the 2012 National Investment Banking Association Conference in New Orleans
5. City of Mason and Top Gun Sales Performance Announce $4 Million Investment In New Corporate Headquarters
6. Enox Biopharma, Inc. Will Present at IN360 Investment in Innovation Conference
7. Regenerative Sciences Receives $2M Investment for Orthopedic Stem Cell Initiatives
8. Foundation Venture Capital Group Makes Eighth Start-Up Investment
9. Israeli Ministry of Finance Hosts Israel Investment, Innovation and Trade Forum in New York
10. David Lichtenstein: Biotechnology is Rich Area for Investment
11. Kansas Bioscience Authority Approves $700,000 in Investments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... , Dec. 22, 2014   ... a developer of pathogen-specific therapies for serious ... protecting the microbiome, today announced positive topline ... 1a clinical trial of SYN-004, the Company,s ... of Clostridium difficile (C. difficile) ...
Breaking Biology Technology:Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... 2008 at 9:00 a.m. Eastern ... ... ALSE ) today reports operational and,financial results for the quarter ended ... http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO ), "We are encouraged by the progress we ...
... Named Contract Manufacturer of Choice, Based on Its ... Based on its recent,analysis of the pharmaceutical ... BioPharma Solutions (BPS) with the 2008 North,American Frost ... Award at,the 2008 Excellence in Healthcare Innovation Awards ...
... Novavax uses strategies to create vaccines for avian flu ... genetically-engineered virus-like particles (VLPs), ROCKVILLE, Md., ... today that its strategy for treating avian flu,through genetically-engineered ... at Cleveland Clinic 6th Annual Medical Innovation,Summit., Novavax, ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 2Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 3Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 4Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results 5Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 2Frost & Sullivan Awards Baxter's BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 2Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 3Cleveland Clinic Recognizes New Strategies for Creating Vaccines for Avian Flu as a Top Ten Medical Innovation for 2009 4
(Date:12/10/2014)...     Jifflenow ...   Jifflenow, a leading provider ... business-to-business (B2B) events, today announced a partnership with ... communication (NFC), Bluetooth low energy (BLE), and cloud-based ... Jifflenow will integrate its meeting scheduling ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014   Atmel® ... leader in microcontroller (MCU) and touch technology solutions, today ... temperature sensors with the widest V cc ... higher temperature accuracy and faster I 2 C bus ... and serial EEPROM memory making them ideal for consumer, ...
Breaking Biology News(10 mins):Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3Inception Technologies to Release New Biometric Reader 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4
... soot or black carbon turns out to be ... to carbon dioxide, according to a four-year assessment by an ... soot particles in smoke and smog, contributes about twice as ... 2007 Intergovernmental Panel on Climate Change. "We were surprised at ...
... bacteria and tree, How the protein transport machinery ... Physcomitrella patens is an evolutionary intermediate stage ... have studied how the protein transport system of ... in the chloroplasts of higher plants. They explored ...
... span eight countries from France to Slovenia and harbour an ... found nowhere else. They are widely considered to be ... biodiversity in Europe. But the Alps are not just ... of up to 14 million people and the destination for ...
Cached Biology News:International study: Where there's smoke or smog, there's climate change 2International study: Where there's smoke or smog, there's climate change 3How the protein transport machinery in the chloroplasts of higher plants developed 2How the protein transport machinery in the chloroplasts of higher plants developed 3In search of the big questions: Conserving the European Alps 2In search of the big questions: Conserving the European Alps 3
Rabbit polyclonal to Aortic Elastin ( Abpromise for all tested applications). entrezGeneID: 2006 SwissProtID: P15502...
Anti-gp120/160(SIV/mac239) Immunogen: gp120(SIV/mac239) protein (Genebank accession #M33262)...
Tropomyosin 4 [Tm4]...
...
Biology Products: